TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $1,403,060.40 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 15,512 shares of the stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total value of $1,403,060.40. Following the sale, the insider now directly owns 25,185 shares in the company, valued at approximately $2,277,983.25. The sale was disclosed in a filing with the SEC, which is accessible through this link.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $93.95 on Friday. The firm has a market capitalization of $3.07 billion, a P/E ratio of -122.01 and a beta of 1.99. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The stock’s 50-day simple moving average is $82.70 and its two-hundred day simple moving average is $71.76. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $99.63.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.22. The firm had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The company’s revenue was up 158.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.21) EPS. As a group, equities analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors have recently modified their holdings of TMDX. FMR LLC increased its position in shares of TransMedics Group by 42.5% during the 3rd quarter. FMR LLC now owns 4,714,870 shares of the company’s stock valued at $258,139,000 after purchasing an additional 1,407,171 shares during the last quarter. Eventide Asset Management LLC increased its position in shares of TransMedics Group by 1,271.7% during the 3rd quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock valued at $50,663,000 after purchasing an additional 857,895 shares during the last quarter. Mackenzie Financial Corp bought a new position in shares of TransMedics Group during the 4th quarter valued at about $35,804,000. Summit Partners Public Asset Management LLC increased its position in shares of TransMedics Group by 71.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company’s stock valued at $59,083,000 after purchasing an additional 400,255 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in TransMedics Group by 91.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after acquiring an additional 363,012 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TMDX. Oppenheimer increased their price objective on TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. JPMorgan Chase & Co. upped their target price on TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Piper Sandler initiated coverage on TransMedics Group in a research note on Thursday, March 28th. They issued an “overweight” rating and a $95.00 target price on the stock. Finally, Morgan Stanley upped their target price on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $102.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.